The current study is a preliminary part of a larger study, validation of the POR polymorphism-related HCC risk and prognosis in additional larger HCC cohorts, and the exact detailed mechanism by which HPN regulates tumor infiltration of immune cells in HCC are needed to verify our results. The gene discussed is HPN; the disease is neoplasm.